Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials.
about
Aspirin in primary prevention of cardiovascular disease and cancer: a systematic review of the balance of evidence from reviews of randomized trialsAspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American CoReview of guidelines on primary prevention of cardiovascular disease with aspirin: how much evidence is needed to turn a tanker?Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians - a population with the highest risk of premature coronary artery disease & diabetesA systematic review of aspirin in primary prevention: is it time for a new approach?Platelet thromboxane (11-dehydro-Thromboxane B2) and aspirin response in patients with diabetes and coronary artery diseaseUpdate on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association.Approach to preventive care in the elderlyAborder les soins préventifs chez les aînésGuidelines on oral anticoagulation with warfarin - fourth editionEffects of combined aspirin and clopidogrel therapy on cardiovascular outcomes: a systematic review and meta-analysisStatins but not aspirin reduce thrombotic risk assessed by thrombin generation in diabetic patients without cardiovascular events: the RATIONAL trialAmelioration of aspirin induced oxidative impairment and apoptotic cell death by a novel antioxidant protein molecule isolated from the herb Phyllanthus niruriRecommending aspirin for primary prevention in diabetic patients: what may we conclude from the data?Cardiovascular Disease in Women: Clinical Perspectives.Diabetes and cardiovascular disease: from evidence to clinical practice - position statement 2014 of Brazilian Diabetes Society.Critical Overview on the Benefits and Harms of Aspirin.Individual and population benefits of daily aspirin therapy: a proposal for personalizing national guidelines.The clinical efficacy and safety evaluation of ticagrelor for acute coronary syndrome in general ACS patients and diabetic patients: A systematic review and meta-analysis.Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus.Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysisCost-effectiveness of aspirin use among persons with newly diagnosed type 2 diabetes.Sex-specific differential in risk of diabetes-related macrovascular outcomesBrazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBAcetylsalicylic acid for primary prevention of cardiovascular diseases in older patients with diabetes: do the benefits overcome the risks?2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by represType 2 diabetes and ASAAspirin resistance: Fact or fiction? A point of view.Aspirin for primary prevention of cardiovascular events: meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status.Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trialAntiplatelet combinations for prevention of atherothrombotic eventsThe missing men: high risk of disease in men of Mexican origin.Differential effect of low-dose aspirin for primary prevention of atherosclerotic events in diabetes management: a subanalysis of the JPAD trialAspirin for primary prevention of cardiovascular disease in diabetes mellitusEvaluation of low-dose aspirin for primary prevention of ischemic stroke among patients with diabetes: a retrospective cohort study.Comparison of treatment outcomes in patients with and without diabetes mellitus attending a multidisciplinary cardiovascular prevention programme (a retrospective analysis of the EUROACTION trial).Low dose of acetylsalicylic acid and oxidative stress-mediated endothelial dysfunction in diabetes: a short-term evaluation.Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: a meta-analysisAspirin: pharmacology and clinical applicationsIs there an additional benefit from coronary revascularization in diabetic patients with acute coronary syndromes or stable angina who are already on optimal medical treatment?
P2860
Q21132402-CC1DD70F-5610-4EB5-8DAD-FFBFE884BAC6Q22241289-4A32FEAA-CA46-4FE3-AB0C-8C1AE1DA9AA7Q22241777-24912D02-1570-497F-8A1F-5510A97FCDA4Q26853571-E2EBD62E-D734-4A64-8F0B-672D514720FDQ26864015-4F3CD326-188B-4DA8-99AE-53375F1FB97DQ27027247-8D4990BD-7E55-4D5C-A3D5-C2CFD1C30B4DQ27687851-EDF6F846-BAD5-4CF7-848A-703697F97064Q28069648-8A1AB604-CEC3-4908-A18A-DC546DDC0032Q28077487-0277A482-A176-43E9-91F6-DEB446C0F741Q28240666-F6FAB3BF-9924-488D-9914-2E88D8A06C07Q28480610-7A9B0208-C5BB-4551-927E-8272363D463FQ28481709-86C71BF6-E28E-409C-9D58-483BE35D3F56Q28539906-FBDA66D0-48D1-45AF-849C-FDF5A04D0134Q30582282-5C0EFB81-2119-47EF-B87F-A0906FE32766Q30743765-9ABCD6F8-0BF1-4B36-8A92-C3D32B29A0ADQ33647298-4FD74714-B330-4BB7-A5EA-037FF6389C08Q33664298-1B298AFE-12D5-4EB9-9CD9-D43D4CE78117Q33689688-44135319-69E6-4E48-836D-17E93B093765Q33699370-3EF96874-FAA8-4381-BD54-E72892BE6B0AQ33706621-79671533-27D5-48D3-BFD7-B6D5AA8B3A73Q33859058-0D44C539-02C5-484C-8DA4-546150D906DCQ33873025-1AE9152B-7AD6-4CC2-872A-5300838B759AQ33905373-76AE42FD-DDA9-4C53-884F-A7977A0CAF6BQ33908782-B7E3B7CB-3065-4920-ADE8-211D2E02EA97Q33949522-61812108-2616-44C9-BD32-E8AAF3F40DB9Q34046881-5769B2A5-B1B6-495F-8475-05BCB2817064Q34070489-E4472E56-DC5A-4483-B9EC-24A8FBD02133Q34389630-1AC0020D-963A-495E-BA19-55A0C5CA9313Q34433987-FB1D5CB6-3AAF-4347-84FB-6E607BDCC586Q34507032-7AAB3245-E442-4548-89EC-1D0488A59124Q34566264-B64F8609-8C88-46A6-8A35-969C8AF067A1Q34970560-0EC37065-45A2-46FD-9136-7CAE3331D4E4Q35043219-B97A558E-7A1E-44B7-AC50-7BDCB3005327Q35132896-E826D5FF-0085-40D8-B631-8E1BD56C87BDQ35136444-E0D41584-BF4F-4307-BCCE-A5CBA2A68124Q35167022-BB9A5A61-5222-46CF-9C1C-CAE9FFDF35CEQ35218036-8B2C75BA-93DB-4B47-8070-979ABCB78D91Q35527043-CA4F4041-5C67-4FC3-958A-FDB6E73AF248Q35608778-4749CEF9-ED19-4476-8D08-F0C301A22B0CQ35691400-4BAC0288-09B8-4852-A313-CEC55567F687
P2860
Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Aspirin for primary prevention ...... randomised controlled trials.
@ast
Aspirin for primary prevention ...... randomised controlled trials.
@en
Aspirin for primary prevention ...... randomised controlled trials.
@nl
type
label
Aspirin for primary prevention ...... randomised controlled trials.
@ast
Aspirin for primary prevention ...... randomised controlled trials.
@en
Aspirin for primary prevention ...... randomised controlled trials.
@nl
prefLabel
Aspirin for primary prevention ...... randomised controlled trials.
@ast
Aspirin for primary prevention ...... randomised controlled trials.
@en
Aspirin for primary prevention ...... randomised controlled trials.
@nl
P2093
P2860
P31
P921
P356
P1433
P1476
Aspirin for primary prevention ...... randomised controlled trials.
@en
P2093
Antonio Nicolucci
Fabio Pellegrini
Gianni Tognoni
Giorgia De Berardis
Giovanni F M Strippoli
Michele Sacco
P2860
P356
10.1136/BMJ.B4531
P407
P5008
P577
2009-11-06T00:00:00Z